Research programme: CNS disorder therapy - Amneal Pharmaceuticals/Indaptus Therapeutics
Latest Information Update: 09 Aug 2021
At a glance
- Originator IMPAX Laboratories; Intec Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 03 Aug 2021 Decoy Biosystems has merged with Intec Pharma to form Indaptus Therapeutics
- 15 Apr 2020 Intec Pharma has several patents and applications related to its Accordion Pill technology, in several countries
- 20 May 2019 Intec Pharma has patent protection for Accordion Pill drug delivery technology in Europe